Porfimer Sodium Articles
Axcan's Photobarr cleared in EU
5 April 2004
Axcan's Photobarr on track for EU approval
5 January 2004
Laserphyrin and Prodif recommended for approval inJapan
29 September 2003
Axcan's Photofrin cleared for new use
11 August 2003
Canada approves Axcan's Photofrin
31 March 2003
Axcan says Photofrin "excellent" in new use
1 July 2002
Axcan files in EU for orphan drug Photobarr
22 April 2002
Axcan gets priority review for Photofrin in Canada
19 July 2001
Sinclair Pharma acquires Italian firm
23 May 2001
Axcan launches Photofrin PDT in UK
8 May 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
Strategic alliance for Axcan and Ferrer
24 July 2000
Axcan acquiring Photofrin from QLT
3 May 2000
Stock Commentary Europe
9 September 1999
Scotia boosted by surprise Phase III results for Foscan
1 September 1999
QLT's shares boosted on Photofrin approval
21 July 1999
BI and QLT terminate Photofrin contract
1 July 1999
Broader US license for Photofrin
7 January 1999
Broader US license for Photofrin
24 December 1998
Beaufour Ipsen Outlines Growth Strategy to 2000
7 October 1998
Herceptin Heads Cancer Drugs Backed In USA
10 September 1998
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
Deep-Acting Photodynamic Compounds
10 February 1998
FDA Clears QLT's PhotoFrin For Lung Cancer
15 January 1998
Positive Phase III Data On Dusa's Levulan
29 October 1997
Scotia "Transformation" Points To Rosier Future
25 September 1997
FDA Panel's Limited OK On QLT's Photofrin Confuses
25 September 1997
Photofrin Approved In Germany; Fall Launch
14 August 1997
Submissions Filed In Canada For Proleukin And Photofrin
7 August 1997
QLT Seeks Photofrin Approval In Canada
9 July 1997
Scotia's Foscan Leads The Way In PDT
7 April 1997
Positive Long-Term Data With QLT's Photofrin
17 March 1997
Beaufour Ipsen Reshaping For Future Growth
3 March 1997
Sanofi To Market QLT's Photofrin In USA
17 February 1997
Beaufour Ipsen And QLT In European Licensing Deal
6 January 1997
QLT Signs Photofrin Deal With Beaufour Ipsen
23 December 1996
QLT Begins Ph III With Photodynamic Drug In Cancer
23 December 1996
Sanofi "Satisfied" In Third Quarter
11 November 1996
Sanofi Grows Oncology Business; Eloxatin Launch
4 November 1996
US Launch Of QLT's Photofrin
14 October 1996
Photofrin Approved In France
22 April 1996
Sanofi To Market Photofrin In USA
15 January 1996
FDA Year-End Approvals Round-Up
8 January 1996
Medi-Physics' Myoview approvable + other approvables
25 September 1995
Canada Approves QLT's Photofrin
31 July 1995
Ciba Vision Launches Betimol In The USA
26 June 1995
Quadra Logic: C$100 Million Sales Forecast
29 May 1995
Photofrin Not Approvable In Belgium
6 March 1995
Ciba Vision, QLT To Work On Ophthalmics
13 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
First World Launch For QLT/Cyanamid's Photofrin
2 January 1995
Marketing Approval For Photofrin In Japan
19 September 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
CONFERENCE REPORT: ASCO MEETING
30 May 1994
NETHERLANDS OKS QUADRA CANCER DRUG
2 May 1994
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
QUADRA LOGIC APPROVAL
26 April 1993
QLT STARTS 2nd GEN CANCER DRUG TRIALS
11 May 1992
Showing 1-61 of 61 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
